CLLSCellectis S.A.Signing up patients
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma (B-NHL)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 80 (planned)
- Started
- Nov 1, 2022
- Main results expected
- Aug 2027
- Fully finished
- Aug 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose finding and expansion parts: Incidence of adverse events/serious adverse events/dose limiting toxicity [Safety and Tolerability]
Measured over: From study entry through month 12
Dose finding part: Occurrence of Dose Limiting Toxicities (DLTs)
Measured over: Up to Day 28 post UCART20x22 infusion
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05607420 · record last updated 2025-08-24 · checked 2026-11-09 15:42 UTC